Effect of Selenium Supplementation on Expression of SIRT1 and PGC-1α Genes in Ulcerative Colitis Patients: a Double Blind Randomized Clinical Trial

• Published in: Clinical nutrition research Vol. 9; no. 4; pp. 284 - 295
• Main Authors: Maryam Khazdouz, Naser Ebrahimi Daryani, Foroogh Alborzi, Mir Hadi Jazayeri, Farnaz Farsi, Motahareh Hasani, Javad Heshmati, Farzad Shidfar
• Format: Journal Article
• Language: Korean
• Published: 한국임상영양학회 30.10.2020
• Subjects: Gene expression; PGC-1alpha protein; Selenium; SIRT1; Ulcerative colitis
• ISSN: 2287-3732; 2287-3740

Selenium (Se) supplementation may decrease the severity of ulcerative colitis (UC) through the activation of genes responsible for immune modulation. The present research was aimed to assess the effect of Se supplementation on the expression of silent information regulator 1 (SIRT1) and peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) in UC patients. In a double-blind randomized parallel clinical trial, 100 patients with mild-to-moderate active UC met inclusion criteria and divided into 2 groups of treatment (50 patients received selenomethionine [200 μg daily]) and placebo (50 patients received placebo [1 capsule daily]) for 10 weeks. The expression rates of SIRT1 and PGC-1α were examined in the peripheral blood mononuclear cell (PBMC) using the real-time polymerase chain reaction. There was no considerable difference in the mean of baseline demographic and clinical characteristics between groups. Also, there were no significant differences in total energy intake, macronutrients, and micronutrients between groups. The SIRT1 gene expression in the Se group was significantly increased compared to the placebo (p < 0.001). An increase in the expression of the PGC-1α gene in the Se group was not statistically significant. It seems that Se supplementation caused a significant decrease in the inflammatory response of the colon by a significant increase in the expression of the SIRT1 gene.